Trump considers vaccine-autism executive order
Analysis based on 13 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026
The potential executive order could introduce regulatory uncertainty for vaccine manufacturers and healthcare providers, potentially affecting vaccine uptake and related revenues. Pharmaceutical and biotech stocks may experience volatility as investors assess the risk of policy changes that could undermine public confidence in vaccines.
The Trump administration is actively considering issuing an executive order on vaccines and autism as soon as next week, according to Bloomberg News, citing people familiar with the matter. The effort is prompted by President Donald Trump's interest in further action, though the contents of the order are unclear and timing could change. This follows Trump's previous linking of autism to childhood vaccines and Tylenol use during pregnancy, claims not supported by scientific evidence. In January, Health Secretary Robert F. Kennedy Jr. reconstituted a federal panel guiding autism policy, appointing 21 new members, some with ties to groups promoting vaccine-autism claims. Kennedy, a longtime anti-vaccine activist, faced a setback in March when a court ruling blocked key elements of his efforts to rewrite U.S. vaccine policy and revamp a CDC advisory panel. Scientific evidence has shown no link between autism and vaccines.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard